SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC
NCT ID: NCT05583409
Last Updated: 2022-10-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
72 participants
INTERVENTIONAL
2023-01-01
2025-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation
NCT03153358
Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial
NCT06481566
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
NCT03667820
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
NCT05009836
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
NCT07058519
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Osimertinib plus SBRT
SBRT with photon and dose is 40Gy/5F after three months after Osimertinib treatment
SBRT+Osimertinib
Received SBRT after three months of Osimertinib treatment
Osimertinib
Osimertinib 80mg, po, Qd
Osimertinib 80 MG
Osimertinib 80mg, po, Qd
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SBRT+Osimertinib
Received SBRT after three months of Osimertinib treatment
Osimertinib 80 MG
Osimertinib 80mg, po, Qd
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients receiving first-line Osimertinib for EGFR mutant-positive for 3 months and achieved stable disease or partial response.
3. Age 18 to 75 years old.
4. Patients must have measurable disease at baseline.
5. The amount of metastatic focus \<5.
6. ECOG score 0-2 7 Adequate normal organ and marrow function for TKI treatment and radiotherapy.
8\. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R) 9. Patients must provide written informed consent to participate in the study.
Exclusion Criteria
2. Patient can't tolerate radiotherapy or targeted therapy;
3. Pregnant or nursing women
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hubei Cancer Hospital
OTHER
Li Zhang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Li Zhang
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Li Zhang, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430030, Hubei, P. R. China
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TJCC-LC002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.